HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on PDS Biotechnology (NASDAQ:PDSB) and maintained a price target of $21.
August 14, 2023 | 3:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PDS Biotechnology's stock may see positive movement due to the reiterated 'Buy' rating and maintained price target by HC Wainwright & Co.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, the 'Buy' rating and $21 price target by HC Wainwright & Co. for PDS Biotechnology could lead to increased investor confidence and potentially positive stock movement in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100